DOI QR코드

DOI QR Code

위 MALT 림프종의 내시경적 소견과 추적관찰

Endoscopic Findings and Follow-Up of Gastric MALT Lymphoma

  • 노진희 (가톨릭대학교 의과대학 내과학교실) ;
  • 이인석 (가톨릭대학교 의과대학 내과학교실)
  • No, Jin Hee (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Lee, In Seok (Department of Internal Medicine, The Catholic University of Korea College of Medicine)
  • 발행 : 2012.12.01

초록

Gastric mucosa-associated lymphoid tissue (MALT) lymphomas comprise over 50% of primary gastric non-Hodgkin lymphomas and show an increasing incidence. Pathogenesis is often related to Helicobacter pylori infection (HPI). Howevere, endoscopic findings of MALT lymphoma are nonspecific and diagnosis is difficult by the naked eye due to various endoscopic appearances such as erosion, erythema, ulceration, atrophy and submucosal mass. Diagnosis is based on the histopathologic evaluation of multiple, deep and repeated biopsies taken from normal and any abnormal appearing sites of the stomach. Endoscopic ultrasound (EUS) can aid in accurate diagnosis, staging, and prediction of prognosis in gastric MALT lymphoma. After treatment of primary gastric lymphoma, EUS produces conflicting results that are not as accurate as endoscopy with biopsy. Therefore, EUS is not mandatory during follow-up. A first evaluation of lymphoma regression should be performed 3-6 months after completion of treatment. Further follow-up should be performed every 4-6 months thereafter until complete remission of lymphoma is documented. Gastroscopy with multiple biopsies has to be performed. Additionally, the initial sites of lymphoma involvement should be checked by appropriate methods. If complete remission of gastric MALT lymphoma is achieved, follow-up gastroscopies with biopsies seem advisable.

키워드

참고문헌

  1. Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years? Br J Haematol 2007;136:521-538. https://doi.org/10.1111/j.1365-2141.2006.06444.x
  2. Mehra M, Agarwal B. Endoscopic diagnosis and staging of mucosa-associated lymphoid tissue lymphoma. Curr Opin Gastroenterol 2008;24:623-626. https://doi.org/10.1097/MOG.0b013e32830bf80f
  3. Cheng H, Wang J, Zhang CS, et al. Clinicopathologic study of mucosa-associated lymphoid tissue lymphoma in gastroscopic biopsy. World J Gastroenterol 2003;9:1270-1272. https://doi.org/10.3748/wjg.v9.i6.1270
  4. Psyrri A, Papageorgiou S, Economopoulos T. Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management. Ann Oncol 2008;19:1992-1999. https://doi.org/10.1093/annonc/mdn525
  5. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575-577. https://doi.org/10.1016/0140-6736(93)91409-F
  6. Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection: MALT Lymphoma Study Group. Lancet 1995;345:1591-1594. https://doi.org/10.1016/S0140-6736(95)90113-2
  7. Roggero E, Zucca E, Pinotti G, et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 1995;122:767-769. https://doi.org/10.7326/0003-4819-122-10-199505150-00006
  8. Urakami Y, Sano T, Begum S, Endo H, Kawamata H, Oki Y. Endoscopic characteristics of low-grade gastric mucosaassociated lymphoid tissue lymphoma after eradication of Helicobacter pylori. J Gastroenterol Hepatol 2000;15:1113-1119. https://doi.org/10.1046/j.1440-1746.2000.02317.x
  9. Choi MK, Kim GH. Diagnosis and treatment of gastric MALT lymphoma. Korean J Gastroenterol 2011;57:272-280. https://doi.org/10.4166/kjg.2011.57.5.272
  10. Taal BG, Boot H, van Heerde P, de Jong D, Hart AA, Burgers JM. Primary non-Hodgkin lymphoma of the stomach: endoscopic pattern and prognosis in low versus high grade malignancy in relation to the MALT concept. Gut 1996;39:556-561. https://doi.org/10.1136/gut.39.4.556
  11. Hyatt BJ, Paull PE, Wassef W. Gastric oncology: an update. Curr Opin Gastroenterol 2009;25:570-578. https://doi.org/10.1097/MOG.0b013e328331b5c9
  12. Youn JC, Lee YC, Youn YH, Kim JH, Yang WI, Chung JB. Two cases of low grade gastric-mucosa-associated lymphoid tissue lymphoma treated by EMR. Gastrointest Endosc 2006;64:456-460. https://doi.org/10.1016/j.gie.2006.02.035
  13. Boot H. Diagnosis and staging in gastrointestinal lymphoma. Best Pract Res Clin Gastroenterol 2010;24:3-12. https://doi.org/10.1016/j.bpg.2009.12.003
  14. Fischbach W. Long-term follow-up of gastric lymphoma after stomach conserving treatment. Best Pract Res Clin Gastroenterol 2010;24:71-77. https://doi.org/10.1016/j.bpg.2009.12.005
  15. Janssen J. The impact of EUS in primary gastric lymphoma. Best Pract Res Clin Gastroenterol 2009;23:671-678. https://doi.org/10.1016/j.bpg.2009.05.008
  16. Asenjo LM, Gisbert JP. Prevalence of Helicobacter pylori infection in gastric MALT lymphoma: a systematic review. Rev Esp Enferm Dig 2007;99:398-404.
  17. Shinagare AB, Ramaiya NH, O'Regan K, Jagannathan JP, Hornick JL, LaCasce AS. Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2011;29:e297-e300. https://doi.org/10.1200/JCO.2010.33.2320
  18. Cha CK, Park S, Kim YB, Lee KM, Cho SW, Hahm KB. The contribution of BCA-1 and apoptosis in gastric MALT lymphoma generation. Korean J Med 2007;72:138-150.
  19. Hummel M, Oeschger S, Barth TF, et al. Wotherspoon criteria combined with B cell clonality analysis by advanced polymerase chain reaction technology discriminates covert gastric marginal zone lymphoma from chronic gastritis. Gut 2006;55:782-787. https://doi.org/10.1136/gut.2005.080523
  20. Ruskone-Fourmestraux A, Fischbach W, Aleman BM, et al. EGILS consensus report: gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011;60:747-758. https://doi.org/10.1136/gut.2010.224949
  21. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001;357:39-40. https://doi.org/10.1016/S0140-6736(00)03571-6
  22. Zucca E, Dreyling M; ESMO Guidelines Working Group. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v175-v176. https://doi.org/10.1093/annonc/mdq182
  23. Kim SG. Gastrointestinal lymphoma. Korean J Gastrointest Endosc 2010;41:1-4.
  24. Song HJ. Treatment and prognosis of gastric MALT lymphoma. Korean J Helicobacter Up Gastrointest Res 2011;11:165-169. https://doi.org/10.7704/kjhugr.2011.11.3.165
  25. Fischbach W, Goebeler ME, Ruskone-Fourmestraux A, et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series. Gut 2007;56:1685-1687. https://doi.org/10.1136/gut.2006.096420
  26. Stathis A, Chini C, Bertoni F, et al. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann Oncol 2009;20:1086-1093. https://doi.org/10.1093/annonc/mdn760

피인용 문헌

  1. Successful Eradication ofHelicobacter pyloriUsing Modified Quadruple Therapy in Patient with Long-lastingH. pylori-induced Active Gastritis vol.14, pp.1, 2014, https://doi.org/10.7704/kjhugr.2014.14.1.52